A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma
10.3349/ymj.2019.60.11.1013
- Author:
Shanping SHI
1
;
Shazhou YE
;
Xiaoyue WU
;
Mingjun XU
;
Renjie ZHUO
;
Qi LIAO
;
Yang XI
Author Information
1. Diabetes Center, Zhejiang Provincial Key Laboratory of Pathophysiology, Institute of Biochemistry and Molecular Biology, Medical School of Ningbo University, Ningbo, Zhejiang, China. xiyang@nbu.edu.cn
- Publication Type:Original Article
- Keywords:
Carcinoma;
renal cell;
biomarkers;
DNA methylation;
prognosis
- MeSH:
Biomarkers;
Carcinoma, Renal Cell;
Classification;
DNA Methylation;
Genome;
Humans;
Methods;
Methylation;
Prognosis;
ROC Curve;
Survival Rate
- From:Yonsei Medical Journal
2019;60(11):1013-1020
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Effective biomarkers and models are needed to improve the prognostic prospects of clear cell renal cell carcinoma (ccRCC). The purpose of this work was to identify DNA methylation biomarkers and to evaluate the utility of DNA methylation analysis for ccRCC prognosis. MATERIALS AND METHODS: An overview of genome-wide methylation of ccRCC tissues derived from The Cancer Genome Atlas (TCGA) database was download for analysis. DNA methylation signatures were identified using Cox regression methods. The potential clinical significance of methylation biomarkers acting as a novel prognostic markers was analyzed using the Kaplan-Meier method and receiver operating characteristic (ROC) curves. RESULTS: This study analyzed data for 215 patients with information on 23171 DNA methylation sites and identified a two-DNA methylation signature (cg18034859, cg24199834) with the help of a step-wise multivariable Cox regression model. The area under the curve of ROCs for the two-DNA methylation signature was 0.819. The study samples were stratified into low- and high-risk classifications based on an optimal threshold, and the two groups showed markedly different survival rates. Moreover, the two-DNA methylation marker was suitable for patients of varying ages, sex, stages (I and IV), and histologic grade (G2). CONCLUSION: The two-DNA methylation signature was deemed to be a potential novel prognostic biomarker of use in increasing the accuracy of predicting overall survival of ccRCC patients.
